Kombination eines CD19 IgA-Antikörpers und einer CD47 Inhibition für die Behandlung der BCP-ALL, Teilprojekt 6 der Klinischen Forschungsgruppe 5010

In this project, we hypothesize that the combination of a CD19-IgA antibody with blockade of CD47 will result in improved recruitment of myeloid effector cells such as granulocytes and macrophages, and therefore better preclinical efficacy in vivo. The results of the proposed experiments will constitute the basis for the translation of clinical protocols combining anti-CD19-IgA constructs with CD47 blockade into early phase clinical trials in adult and pediatric ALL. Such strategies may be particularly relevant in subgroups with an urgent need for therapy optimization, such as KMT2A-rearranged disease at all ages.